2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. Eukaryotic Initiation Factor (eIF)

Eukaryotic Initiation Factor (eIF)

Eukaryotic Initiation Factor (eIF)

Related Products

PDF 0.58 MB

Eukaryotic initiation factors (eIFs) are proteins involved in the initiation phase of eukaryotic translation. These proteins help stabilize the formation of the functional ribosome around the start codon and also provide regulatory mechanisms in translation initiation.

Eukaryotic initiation factor 2B (eIF2B) is a guanine nucleotide-exchange factor which mediates the exchange of GDP (bound to initiation factor eIF2) for GTP, thus regenerating the active [eIF2.GTP] complex that is required for peptide-chain initiation. The activity of eIF2B is a key control point for eukaryotic protein synthesis and is altered in response to viral infection, hormones, nutrients, growth factors and certain stresses.

Eukaryotic translation initiation factor 4E (eIF4E) is best known for its function in the initiation of protein synthesis on capped mRNAs in the cytoplasm. Eukaryotic initiation factor (elF) 4A functions as a subunit of the initiation factor complex elF4F, which mediates the binding of mRNA to the ribosome.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-W010451
    1,2,4-Trihydroxybenzene
    		Activator 99.96%
    1,2,4-Trihydroxybenzene (Hydroxyhydroquinone) is an ER stress inducer that targets proteins such as PKR-like ER kinase PERK to induce cytotoxicity. 1,2,4-Trihydroxybenzene selectively activates eIF2α phosphorylation, activates the PERK-eIF2α signaling pathway and induces stress granule formation. 1,2,4-Trihydroxybenzene subsequently exacerbates oxidative stress and causes DNA double-strand breaks, destroying organelles such as mitochondria and ER, and inducing cell death. 1,2,4-Trihydroxybenzene also has the potential to exhibit anti-tumor effect, increase blood pressure, and relieve spasm.
    1,2,4-Trihydroxybenzene
  • HY-19831A
    (Z)-4EGI-1
    		Inhibitor 98.0%
    (Z)-4EGI-1 is the Z-isomer of 4EGI-1 and is an inhibitor of eIF4E/eIF4G interaction and of translation initiation. (Z)-4EGI-1 effectively binds to eIF4E with an IC50 of 43.5 μM and a Kd value of 8.74 μM. (Z)-4EGI-1 has anticancer activity.
    (Z)-4EGI-1
  • HY-W018587
    TBPH
    TBPH is a brominated flame retardant. TBPH enhances hepatic steatosis, inflammation, and fibrosis in mice with nonalcoholic steatohepatitis (NASH). TBPH induces dysregulation of phospholipid metabolism, reducing cardiolipin (CL) and phosphatidylserine (PS) levels. TBPH leads to impaired endoplasmic reticulum-mitochondria (ER-Mito) contacts, subsequently causing mitochondrial dysfunction. TBPH induces lung injury through an inflammatory response mediated by mitochondria-derived ds-DNA. TBPH can be used to study the role of MFN2-mediated ER-mitochondria contacts in lipid metabolism homeostasis.
    TBPH
  • HY-153074
    ISR-IN-1
    		Modulator 98.92%
    ISR-IN-1 (Compound 48) is an inhibitor of the integrated stress response (EC50: 0.6 nM).
    ISR-IN-1
  • HY-101991
    ML291
    		Activator 99.80%
    ML291 is a UPR (unfolded protein response)-inducing sulfonamidebenzamide. ML291 overwhelms the adaptive capacity of the UPR and induces apoptosis in a variety of solid cancer models. ML291 can activate the PERK/eIF2a/CHOP (apoptotic) arm of the UPR and reduce leukemic cell burden.
    ML291
  • HY-153075
    ISR-IN-2
    ISR-IN-2 (Compound 47) is an inhibitor of the integrated stress response (EC50: 0.8 nM).
    ISR-IN-2
  • HY-146805
    EB1
    		Inhibitor 99.91%
    EB1 is the inhibitor of kinases MNK with IC50s of 0.69 μM (MNK1) and 9.4 μM (MNK2). EB1 selectively inhibits the growth of cancer cells, but not normal cells. EB1 also increases cell apoptosis and suppresses eIF4E phosphorylation.
    EB1
  • HY-176428
    PROTAC MNK1 degrader-1
    		Inhibitor 98.93%
    PROTAC MNK1 degrader-1 is a selective MNK1 PROTAC degrader with a DC50 of 11.92 nM, and a Dmax > 96% in MV4-11 cells. PROTAC MNK1 degrader-1 significantly reduces p-eIF4E (IC50: 22.07 nM), induces apoptosis, and arrests the cell cycle at the G1 phase. PROTAC MNK1 degrader-1 has potent antitumor activity. PROTAC MNK1 degrader-1 has robust antileukemic efficacy in MV4-11 xenograft mice model with acceptable drug safety. Pink: MNK1 ligand (HY-176429); Blue: CRBN ligase ligand (HY-A0003); Black: linker (HY-Y1139); CRBN + linker: HY-176430
    PROTAC MNK1 degrader-1
  • HY-15359
    Episilvestrol
    		Inhibitor 99.86%
    Episilvestrol is a derivative of silvestrol, isolated from the fruits and twigs of Aglaia perviridis, and is a specific eIF4A-targeting translation inhibitor, with antitumor activity.
    Episilvestrol
  • HY-W319647
    GCN2 activator-1
    		Inhibitor 99.69%
    GCN2 activator-1 (Compound 20) is a GCN2 activator. GCN2 activator-1 binds within the ATP-pocket of GCN2 and activates GCN2 in a GCN1-independent manner. GCN2 activator-1 activates Integrated Stress Response (ISR) in cells. GCN2 activator-1 inhibits PKR with an IC50 of 3.75 µM. GCN2 activator-1 can be used for research of pulmonary veno-occlusive disease (PVOD).
    GCN2 activator-1
  • HY-112163A
    rel-Zotatifin
    		Inhibitor
    rel-Zotatifin is the racemic isomer of Zotatifin, acts as an eIF4A inhibitor with activity less than Zotatifin. Zotatifin (eFT226) is a potent, selective, and well-tolerated eIF4A inhibitor. Zotatifin promotes eIF4A binding to specific mRNA sequences with recognition motifs in the 5’-UTRs (IC50=2 nM) and interferes with the assembly of the eIF4F initiation complex.
    rel-Zotatifin
  • HY-148452
    eIF4A3-IN-18
    		Inhibitor 99.58%
    eIF4A3-IN-18 (compound 74) is a Silvestrol (HY-13251) analogue. eIF4A3-IN-18 interferes the assembling of eIF4F translation complex with EC50 values of 0.8, 35 and 2 nM for myc-LUC, tub-LUC and the growth inhibition for MBA-MB-231 cells. eIF4A3-IN-18 also has cytotoxicity to RMPI-8226 cells with an LC50 of 0.06 nM. eIF4A3-IN-18 can be used for the research of human cancer pathogenesis.
    eIF4A3-IN-18
  • HY-43913
    (R)-eIF4A3-IN-2
    (R)-eIF4A3-IN-2 is a less active enantiomer of eIF4A3-IN-2. eIF4A3-IN-2 is a highly selective and noncompetitive eukaryotic initiation factor 4A-3 (eIF4A3) inhibitor with an IC50 of 110 nM.
    (R)-eIF4A3-IN-2
  • HY-148105
    DS12881479
    		Inhibitor 99.63%
    DS12881479 is a selective non-ATP-competitive MNK1 inhibitor with an IC50 value of 387 nM. DS12881479 stabilizes MNK1 in its autoinhibited DFD-out conformation, blocks eIF4E phosphorylation, suppresses tumor cell proliferation and induces weak apoptosis. DS12881479 also inhibits FLT3 and DYRK1a kinase activity at high concentrations. DS12881479 can be used for the research of cancer, such as leukemia.
    DS12881479
  • HY-153399A
    Fosigotifator THAM sodium
    		Activator 98.03%
    Fosigotifator (ABBV-CLS-7262) THAM sodium is a brain penetrant, orally active EIF2b (eukaryotic initiation factor) activator. Fosigotifator THAM sodium stabilizes the elF2B complex and boosts the activity, including that of complexes carrying pathogenic vanishing white matter (VWM) mutations. Fosigotifator THAM sodium is an integrated stress response inhibitor (ISRI). Fosigotifator THAM sodium can be used for amyotrophic lateral sclerosis research.
    Fosigotifator THAM sodium
  • HY-155068
    FC-116
    		Inhibitor 98.04%
    FC-11 is a tubulin inhibitor. FC-116 inhibits the proliferation of colorectal cancer (CRC) cells, with IC50 values of 4.52 nM for HCT116 cells and 18.69 nM for CT26 cells. FC-11 can induce ER stress to generate excess ROS, leading to mitochondrial damage, thereby promoting apoptosis in colorectal cancer (CRC) cells by targeting microtubules. FC-116 exerts potent anti-tumor effects in vivo. FC-11 can be used for the study of colorectal cancer.
    FC-116
  • HY-148446
    eIF4A3-IN-12
    		Inhibitor 99.70%
    eIF4A3-IN-12 (compound 62) is a Silvestrol (HY-13251) analogue. eIF4A3-IN-12 interferes the assembling of eIF4F translation complex with EC50s of 4, 70 and 5 nM for myc-LUC, tub-LUC and the growth inhibition for MBA-MB-231 cells. eIF4A3-IN-12 can be used for the research of human cancer pathogenesis.
    eIF4A3-IN-12
  • HY-145309
    eIF4E-IN-3
    		Inhibitor
    eIF4E-IN-3 (Example 485) is a eIF4E inhibitor with an IC50 of 0.00859 μM. eIF4E-IN-3 inhibits the activity of eIF4E. eIF4E-IN-3 is used in cancer research.
    eIF4E-IN-3
  • HY-148449
    eIF4A3-IN-15
    		Inhibitor
    eIF4A3-IN-15 (compound 52) is a Silvestrol (HY-13251) analogue. eIF4A3-IN-15 interferes the assembling of eIF4F translation complex with EC50s of 11, 700 and 120 nM for myc-LUC, tub-LUC and the growth inhibition for MBA-MB-231 cells. eIF4A3-IN-15 can be used for the research of human cancer pathogenesis.
    eIF4A3-IN-15
  • HY-148443
    eIF4A3-IN-9
    		Inhibitor 99.71%
    eIF4A3-IN-9 is a Rocaglate analog. eIF4A3-IN-9 interferes with the assembly of the eIF4F translation complex, with EC50 values of 29 and 450 nM against myc-LUC and tub-LUC, respectively. eIF4A3-IN-9 can be used for the research of tumor pathogenesis.
    eIF4A3-IN-9
Cat. No. Product Name / Synonyms Application Reactivity